{"id":"W4405042935","doi":"10.1182/blood-2024-203757","title":"Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Tolerability; Medicine; Myeloid leukemia; Tyrosine-kinase inhibitor; Internal medicine; Tyrosine kinase; Nilotinib; Phases of clinical research; Oncology; Imatinib; Pharmacology; Adverse effect; Clinical trial; Cancer; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002012003,0.0007620113,0.0009558257,0.0002652566,0.0002695971,0.0006459111,0.0004171107,0.0005287175,0.003869604],"category_scores_gemma":[0.001022441,0.0002595445,0.0009018587,0.0003545306,0.000380026,0.0005829044,0.0002646518,0.001723747,0.0006506689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005197166,"about_ca_system_score_gemma":0.0009859444,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005820823,"about_ca_topic_score_gemma":0.002126047,"domain_scores_codex":[0.9995081,0.000263285,0.00003607447,0.00005499976,0.00007090385,0.00006654826],"domain_scores_gemma":[0.9988716,0.0002177861,0.0003249772,0.00008243617,0.0001039358,0.0003992522],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7788781,0.02321802,0.01489967,0.0008045741,0.001862048,0.0001862494,0.0001623869,0.001627135,0.02382291,0.0002780011,0.01056915,0.1436919],"study_design_scores_gemma":[0.3968877,0.5132583,0.06549928,0.00007667147,0.001719567,0.0005771628,0.00007614971,0.001876906,0.009895014,0.000327407,0.009758012,0.00004773828],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909763,0.002878753,0.0004697763,0.0005351543,0.0001220423,0.000730283,0.001913894,0.0000843535,0.002289449],"genre_scores_gemma":[0.9915199,0.001579152,0.0009983428,0.0005338912,0.0002387627,0.0004043278,0.002551713,0.00002637498,0.00214751],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003869604,"threshold_uncertainty_score":0.01294506,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01849470641750113,"score_gpt":0.2865542485673685,"score_spread":0.2680595421498674,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}